Back to discover
Disease
Pregnancy in Diabetics
Late-stage therapeutic developmentEmerging research
1
Publications
24
Clinical trials
2025
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2025-05-06Diabetes, obesity & metabolism
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
- Q2 2027Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes
- Q3 2027A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Q3 2027Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR Study
- Q4 2027Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20272026-06-26
Upcoming trial readoutHigh impact
Results expected Q2 20272026-04-21
Clinical MilestonesView all 13Hide
Results posted
Results expected
- 2026-06-26A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-21Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 DiabetesResults expected Q2 2027
- 2026-04-20A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
- 2026-01-13Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR StudyResults expected Q3 2027
Other updates
- 2029-02-28Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
+5 more in the activity timeline below
Activity timeline13
- 2029-02-28ClinicalEvaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31ClinicalIntervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01ClinicalA Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01ClinicalPhase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01ClinicalComparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2026-06-30ClinicalMetformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized TrialWithdrawn
- 2026-06-26ClinicalA Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-21ClinicalEfficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 DiabetesResults expected Q2 2027
- 2026-04-20ClinicalA Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18ClinicalA 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes4
- Diabetes Mellitus, Type 21
- Glucagon-Like Peptide-1 Receptor Agonists1
- Hypoglycemic Agents1
- Pregnancy in Diabetics1
Leading journals1
- Diabetes, obesity & metabolism1
Leading researchers4
- Brennan DJ1
- le Roux CW1
- Parker CH1
- Slattery C1
Affiliations (unnormalised)4
- Diabetes Complications Research Centre1
- Renaissance School of Medicine at Stony Brook University1
- School of Biomolecular and Biomedical Science1
- University College Dublin School of Medicine1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
The state of PREGNANCY in women with DIABETES MELLITUS. This does not include either symptomatic diabetes or GLUCOSE INTOLERANCE induced by pregnancy (DIABETES, GESTATIONAL) which resolves at the end of pregnancy.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.